Advertisement Analysing a Biomarker as a Proof of Concept - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
More info about

Analysing a Biomarker as a Proof of Concept

CASE STUDIES
By

Two doses of a therapeutic vaccine were tested simultaneously in a randomized phase II trial. While the trial’s primary endpoint was not sensitive enough to show efficacy of either dose or any difference between the two, using the advanced statistical methodology of mixed modelling on repeated measures, it was found that the high dose had a highly significant effect on a relevant biomarker, while the low dose had no such effect.

Quick Contact


Top Products from